Biosimilar Monoclonal Antibodies Market
Biosimilar Monoclonal Antibodies Market Scope:
Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Biosimilar Monoclonal Antibodies Market Size and Growth
The Biosimilar Monoclonal Antibodies market is witnessing significant growth, driven by increasing demand for cost-effective alternatives to expensive biologics. Market size is projected to reach approximately $41 billion by 2027, influenced by advancements in biotechnology and regulatory support. Competitive dynamics and patient accessibility are critical factors shaping market conditions. Request Sample Report
Companies Covered (Covid 19 Impact Covered)
◍ Celltrion
◍ Pfizer (Hospira)
◍ 3SBIO
◍ Novartis (Sandoz)
◍ Dr Reddy’s
◍ Celgen Biopharma
◍ Cadila Healthcare
◍ Hisun Pharma
◍ Torrent Pharmaceuticals
The biosimilar monoclonal antibodies market features key players like Celltrion, Pfizer (Hospira), 3SBIO, Novartis (Sandoz), Dr. Reddy’s, Celgen Biopharma, Cadila Healthcare, Hisun Pharma, and Torrent Pharmaceuticals. These companies innovate and expand access to biosimilars, driving market growth and increasing revenue through competitive pricing and strategic partnerships.
- Pfizer (Hospira): Reported $4.2 billion in biosimilars revenue (2022).
- Novartis (Sandoz): Generated $1.3 billion from biosimilars (2022).
- Celltrion: Achieved $1.1 billion in biosimilar sales (2021).
Request Sample Report
Market Segmentation
By Application
Oncology
Autoimmune Disease
By Product
◍ Infliximab
Rituximab
Other Request Sample Report
Trastuzumab
Adalimumab
Other
Market Growth
Request Sample Report
$ X Billion USD
